Ani Pharmaceuticals (ANIP) Debt to Equity (2012 - 2026)

Ani Pharmaceuticals has disclosed Debt to Equity across 12 years of filings, most recently posting $0.54 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.54, down 5.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.54 (down 5.63% YoY), and the FY2025 annual result was $0.57, down 99.04% from the prior year.
• Debt to Equity came in at $0.54 for Q1 2026 at Ani Pharmaceuticals, down from $0.57 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $155134.5 in Q2 2023 to a low of -$60.59 in Q2 2022.
• The 5-year median for Debt to Equity is $0.61 (2024), against an average of $26616.0.
• Across the five-year window, Debt to Equity sank 5780.25% in 2022 and jumped 20135038.47% in 2023, its largest moves.
• Ani Pharmaceuticals' Debt to Equity stood at $0.71 in 2022, then surged by 20135038.47% to $142834.5 in 2023, then tumbled by 99.96% to $59.56 in 2024, then plunged by 99.04% to $0.57 in 2025, then declined by 5.02% to $0.54 in 2026.
• The last three Debt to Equity figures came in at $0.54 (Q1 2026), $0.57 (Q4 2025), and $0.62 (Q3 2025), per Business Quant data.